CLONAZEPAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H10ClN3O3
Molecular Weight	315.711
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C3=C(Cl)C=CC=C3)C=C1

InChI

InChIKey=DGBIGWXXNGSACT-UHFFFAOYSA-N

InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

HIDE SMILES / InChI

Molecular Formula	C15H10ClN3O3
Molecular Weight	315.711
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017533s053,020813s009lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/25798598

Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Klonopin is the brand name for Clonazepam, an anxiolytic and anticonvulsant. The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
GABA-A receptor; anion channel 202 Target ID: CHEMBL2093872 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/8727390 \| https://www.ncbi.nlm.nih.gov/pubmed/25798598	Agonist 2678	0.06 nM [EC50]
GABA-A receptor; alpha-1/beta-2/gamma-2 27 Target ID: CHEMBL2095172 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25798598	Agonist 2678	57.0 µM [EC50]
GABA A receptor alpha-2/beta-2/gamma-2 6 Target ID: CHEMBL2111413 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25798598	Agonist 2678	40.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Seizure disorders 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf	Primary		Approved 8429	KLONOPIN Approved Use INDICATIONS & USAGE Seizure Disorders: Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and . In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Panic Disorder: Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder. Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Launch Date 1975
Panic disorder 22 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf	Primary		Approved 8429	KLONOPIN Approved Use INDICATIONS & USAGE Seizure Disorders: Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and . In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Panic Disorder: Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder. Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Launch Date 1975

C_max

Value	Dose	Co-administered	Analyte	Population
2.3 ng/mL EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3 ng/mL REVIEW https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		CLONAZEPAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
102 ng × h/mL EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
339 ng × h/mL REVIEW https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		CLONAZEPAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 h REVIEW https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		CLONAZEPAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
15% EXPERIMENT https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		CLONAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 mg single, intramuscular Dose: 2 mg Route: intramuscular Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	Sources: https://pubmed.ncbi.nlm.nih.gov/12646763
2 mg single, intravenous Dose: 2 mg Route: intravenous Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	Sources: https://pubmed.ncbi.nlm.nih.gov/12646763
2 mg single, oral Dose: 2 mg Route: oral Route: single Dose: 2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12646763	Sources: https://pubmed.ncbi.nlm.nih.gov/12646763
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	Disc. AE: Somnolence, Depression... AEs leading to discontinuation/dose reduction: Somnolence (7%) Depression (4%) Nervousness (1%) Dizziness (1%) Ataxia (1%) Intellectual disability (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
6 mg 1 times / day steady, oral Studied dose Dose: 6 mg, 1 times / day Route: oral Route: steady Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3279721	unhealthy Health Status: unhealthy Condition: depression Sources: https://pubmed.ncbi.nlm.nih.gov/3279721	Sources: https://pubmed.ncbi.nlm.nih.gov/3279721

AEs

AE	Significance	Dose	Population
Ataxia	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Dizziness	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Intellectual disability	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Nervousness	1% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Depression	4% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf
Somnolence	7% Disc. AE	1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 810 CYP2E1 882 UGT 35	CYP3A 191 BCRP 561	CYP 76 UGT 29

Drug as perpetrator

Target	Modality	Activity
CYP 147	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218/	no
UGT 59	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218/	no
UGT 59	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218/	no
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	weak
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9574817/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
BCRP 561	substrate 3367 Sources: https://www.wjgnet.com/2220-3192/full/v3/i4/153.htm	no
CYP3A 191	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017533s061lbl.pdf#page=2 Page: 2.0	yes
CYP3A4 1737	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203763/	yes	yes (pharmacogenomic study) Comment: The statistical analysis displayed significant association between the patients’ CYP3A4 expression and the stable plasma concentrations of clonazepam normalized by the dose and the patient’s bodyweight. Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203763/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3756	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3756
ZINC	ZINC000003813003	http://zinc15.docking.org/substances/ZINC000003813003
eMolecules	535779	https://www.emolecules.com/cgi-bin/more?vid=535779

PubMed

Title	Date	PubMed
Letter: Clonazepam in the treatment of drug-induced dyskinesia.	1975 Feb 1	1111773
Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder.	1999 Dec	10646174
Benztropine for venlafaxine-induced night sweats.	2000 Apr	10770471
Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats.	2000 Feb	10728915
Interstrain differences in cognitive functions in rats in relation to status epilepticus.	2000 Jul	10862938
Seizure-inducing paradoxical reaction to antiepileptic drugs.	2000 Jun	10838112
Gabapentin prophylaxis of clozapine-induced seizures.	2000 Mar	10698845
Pharmacological options for the treatment of Tourette's disorder.	2001	11772131
Insomnia and fronto-basal tumor: a case report.	2001	11455188
Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis.	2001	11299059
[Clonazepam in therapy of neurogenic syncopal states].	2001	11243029
Sensitivity to the effects of sedative-hypnotics on motor performance: influence of task difficulty and chronic phenobarbital administration.	2001 Apr	11396517
Semiautomated high-performance liquid chromatographic method for the determination of benzodiazepines in whole blood.	2001 Apr	11327354
Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam.	2001 Apr	11313161
Benzodiazepines protect against ethanol-induced gastric mucosal damage in vitro.	2001 Aug	11564131
Carbamazepine treatment of corticosteroid-induced mood disorder.	2001 Aug	11511412
Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.	2001 Aug	11498064
Smoking and panic disorder.	2001 Aug	11474063
Mitochondria recycle Ca(2+) to the endoplasmic reticulum and prevent the depletion of neighboring endoplasmic reticulum regions.	2001 Aug 3	11358971
[Cortico-subcortical electrophysiological study during the effects of benzodiazepines in patients with panic disorders].	2001 Feb 16-28	11333385
Evaluation of native GABA(A) receptors containing an alpha 5 subunit.	2001 Feb 9	11173064
Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats.	2001 Jan	11151029
Benign segmental myoclonus: electrophysiological evidence of transient dysfunction in the brainstem.	2001 Jan	11148081
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.	2001 Jan	11137387
Case report: unexplained syncope explained.	2001 Jul	11494931
Involuntary movements in infantile cobalamin deficiency appearing after treatment.	2001 Jul	11483404
Acquired epileptiform opercular syndrome: a case report and results of single photon emission computed tomography and computer-assisted electroencephalographic analysis.	2001 Jul	11377005
Burning mouth syndrome after taking clonazepam.	2001 Jul-Aug	11485137
Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.	2001 Mar-Apr	11787948
[3H]Flunitrazepam binding to recombinant alpha1beta2gamma2S GABAA receptors stably expressed in HEK 293 cells.	2001 May	11393809
Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm.	2001 May 18	11368960
West syndrome: the Philippine experience.	2001 Nov	11701266
Increased [Mg2+]o reduces Ca2+ influx and disruption of mitochondrial membrane potential during reoxygenation.	2001 Nov	11668073
Influence of age and comedication on steady-state clonazepam serum level-dose ratios in Japanese epileptic patients.	2001 Oct	11679028
2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands.	2001 Oct	11557354
[Efficacy of anticonvulsants on acute encephalitis with refractory, repetitive partial seizures (AERRPS)].	2001 Sep	11558140
Topiramate as a mood stabilizer.	2001 Sep	11552774
Effect of midazolam on interleukin-6 mRNA expression in human peripheral blood mononuclear cells in the absence of lipopolysaccharide.	2001 Sep 21	11594799
Burning mouth syndrome.	2001 Summer	11603307

Patents

Sample Use Guides

In Vivo Use Guide

Seizure Disorders: Adults: The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg. Clonazepam is available as a tablet or an orally disintegrating tablet (wafer). The tablets should be administered with water by swallowing the tablet whole. The orally disintegrating tablet should be administered as follows: After opening the pouch, peel back the foil on the blister. Do not push tablet through foil. Immediately upon opening the blister, using dry hands, remove the tablet and place it in the mouth. Tablet disintegration occurs rapidly in saliva so it can be easily swallowed with or without water.

Route of Administration: Oral

In Vitro Use Guide

Clonazepam (100 nM) increased inhibitory postsynaptic current (IPSC) decay time constants in rat thalamic nuclei-the reticular nucleus (nRt) (from 44.3 to 77.9 ms, P < 0.01) but not in the ventrobasal (VB) complex..

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:55:06 GMT 2023` Edited by `admin` on `Sat Dec 16 16:55:06 GMT 2023`
Record UNII	5PE9FDE8GB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLONAZEPAM

Official Name

English

NSC-179913

Code

English

CLONAZEPAM [JAN]

Common Name

English

RIVOTRIL

Brand Name

English

RO-5-4023

Code

English

CLONAZEPAM [MART.]

Common Name

English

RIVATRIL

Brand Name

English

RO 5-4023

Code

English

2H-1,4-BENZODIAZEPIN-2-ONE, 5-(2-CHLOROPHENYL)-1,3-DIHYDRO-7-NITRO-

Systematic Name

English

Clonazepam [WHO-DD]

Common Name

English

CLONAZEPAM [ORANGE BOOK]

Common Name

English

5-(O-CHLOROPHENYL)-1,3-DIHYDRO-7-NITRO-2H-1,4-BENZODIAZEPIN-2-ONE

Common Name

English

CLONAZEPAM [MI]

Common Name

English

KLONOPIN

Brand Name

English

CLONAZEPAM [EP MONOGRAPH]

Common Name

English

RO-54023

Code

English

clonazepam [INN]

Common Name

English

RAVOTRIL

Brand Name

English

CLONAZEPAM [VANDF]

Common Name

English

CLONAZEPAM CIV [USP-RS]

Common Name

English

CLONAZEPAM [HSDB]

Common Name

English

CLONAZEPAM CIV

Common Name

English

CLONAZEPAM [USAN]

Common Name

English

CLONAZEPAM [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175694